Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD) and is characterized by the presence of an abnormal accumulation of fat in the liver.
NASH is a chronic yet silent disease, which means that most patients live with it for several years without experiencing any symptoms and are mostly unaware of their liver condition. NASH clinical trials, like those at CNS Healthcare, can help you explore new options. Interested in trying a new NASH treatment at no cost? Find out more about enrolling NASH clinical trials available by selecting one of the below locations near you. Use the form on the page to schedule a free, in-office consultation to find out if a NASH trial is right for you.
Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD) and is characterized by the presence of an abnormal accumulation of fat in the liver which in some individuals can progress to liver cell injury (hepatocellular ballooning) and inflammation. Hepatocellular ballooning and inflammation are commonly considered as the drivers of disease progression, or as the underlying causes of the disease. As NASH evolves, over time it can result in excessive scarring in the liver (fibrosis), cirrhosis or liver cancer.
You may be more likely to have NASH if you:
The diagnosis should be suspected in patients with risk factors such as obesity, type 2 diabetes mellitus, or dyslipidemia and in patients with unexplained laboratory abnormalities suggesting liver disease. The only way to diagnose NASH is through a liver biopsy.
Most patients are asymptomatic. However, some may have: